Anteris Technologies Global Corp. — AGM Information 2009

Nov 10, 2009

==> picture [596 x 64] intentionally omitted <==

Innovative BioMedical Devices ABN 35 088 221 078

bioMD Limited Level 11, 225 St Georges Terrace Perth, Western Australia 6000 PO Box 7209, Cloisters Square Western Australia 6850

Telephone (08) 9262 6777 Facsimile (08) 9322 3433 ABN 35 088 221 078 www.biomd.com.au

ANNOUNCEMENT TO THE AUSTRALIAN STOCK EXCHANGE

1 of 12 pages

11 November 2009

Company Announcements Office Australian Stock Exchange Limited 10th Floor, 20 Bond Street SYDNEY NSW 2000

ANNUAL GENERAL MEETING PRESENTATION

The Directors of bioMD Limited are pleased to announce the Presentation for the 6[th] Annual General Meeting of the Company to be held today.

Yours faithfully

==> picture [79 x 59] intentionally omitted <==

Caroline Bentley Company Secretary

==> picture [596 x 42] intentionally omitted <==

Annual General Meeting

11 November 2009

==> picture [720 x 78] intentionally omitted <==

OUTLOOK 2009/2010 - Biomaterial Mesh Patches utilising the ADAPT Tissue Engineering Process

• A heart deformity human clinical trial completed

• interim report due Dec 2009

• final report mid 2010;

• A pelvic floor reconstruction human clinical trial in progress;

• Australian manufacturing plan for ADAPT biomaterial mesh patch;

==> picture [200 x 150] intentionally omitted <==

• Global regulatory applications being implemented - TGA/FDA/CE;

• Commercialisation partnerships being explored for specialty products, e.g. tissue heart valves;

• Currently these include a feasibility study plan being negotiated with a global heart valve company;

==> picture [720 x 78] intentionally omitted <==

CARDIOVASCULAR HUMAN CLINICAL TRIAL SAFETY & EFFICACY RESULTS 30 patient study evaluating the performance of the ADAPT treated CardioCel pericardial patch for heart deformities - completed October 2009

==> picture [73 x 96] intentionally omitted <==

==> picture [237 x 173] intentionally omitted <==

• No patch-related clinical adverse effects;

• No additional calcification at 6 month follow-up;

• Safety, efficacy and clinical performance proven in a demanding surgical environment;

• Provided platform of security to pursue other human clinical studies;

==> picture [720 x 78] intentionally omitted <==

HUMAN PELVIC FLOOR REPAIR PILOT STUDY 20 women requiring Anterior Vaginal Prolapse repair to be enrolled – clinical trial already commenced with first patients due for follow-up by end 2009

==> picture [78 x 103] intentionally omitted <==

• “

• • GYNECEL” - a biomaterial mesh ideal for all abdominal

• soft tissue repairs;

• Remodels into host tissue and avoids erosions often experienced with synthetic meshes;

• Global market in 2007 >USD1 billion (projected >USD1.5 billion in 2011**);

==> picture [129 x 83] intentionally omitted <==

• Expanding market (>15% p.a.) due to “quality of life” demands.

• ** Millennium Research “Global markets for Soft Tissue Repair, 2008”

==> picture [206 x 207] intentionally omitted <==

==> picture [720 x 78] intentionally omitted <==

THE GLOBAL MARKET – BIOMATERIAL MESH 2010

• Significant acquisition activity amongst global players – sector strengthening in biomaterial tissue technologies versus synthetics - e.g. Covidien/TSL, Kinetic/LifeCell, Synovis/Pegasus, RTI Biologics;

• Surgical fields including cardiovascular, abdominal and orthopedic with combined global revenue projected 2011 of >USD2 billion;

• Surgical fields of emphasis by US companies is presently concentrated on hernia repair and breast reconstruction;

• Surgical community concerned at poor performance of current competitor products and seeking better patient outcomes;

==> picture [720 x 78] intentionally omitted <==

COMPETITION / MARKET DRIVERS

Synovis Life Technologies Inc. – Veritas Ventral Hernia Repair Patch CEO, third quarter of fiscal 2009 –

==> picture [78 x 103] intentionally omitted <==

“We again posted double-digit revenue gains and realized the 12[th] record revenue quarter in the last 13 quarters. Revenue from patch products based on Synovis’ unique Veritas remodelable biomaterial rose to $2.3 million in the third quarter ……….Synovis launched Veritas into the ventral hernia repair market in 2007 ……Veritas has demonstrated performance advantages and we continue to see exceptional revenue

==> picture [720 x 78] intentionally omitted <==

ADAPT TECHNOLOGY APPLICATIONS The ADAPT Tissue Engineering Process can be used to produce the following biomaterial devices:

• Existing tissue heart valves – valve leaflets;

• New percutaneous heart valves;

• Cardiovascular heart biomaterial mesh patches;

• Pelvic floor reconstruction biomaterial mesh;

• Hernia biomaterial mesh;

• Orthopaedic rotator cuff and tendon repair implants;

==> picture [140 x 186] intentionally omitted <==

• Suture/staple line reinforcement;

==> picture [720 x 78] intentionally omitted <==

ADAPT Biomaterial Products

Mesh Product Pre-clinical Phase I/II Regulatory Marketed Candidate CardioCel Gynecel Hernia Mesh Breast Reconstruction Orthopaedics

==> picture [680 x 38] intentionally omitted <==

==> picture [720 x 78] intentionally omitted <==

KEY COMMERCIALISATION MILESTONES ACHIEVED AND IN PROGRESS	KEY COMMERCIALISATION MILESTONES ACHIEVED AND IN PROGRESS	KEY COMMERCIALISATION MILESTONES ACHIEVED AND IN PROGRESS
Completed 30 patient heart patch trial (safety & efficacy)	Q209	~~�~~ �
Started 20 patient pelvic floor reconstruction (PFR) clinical trial	Q309	�
Interim report 20 patient PFR study	Q210	~~�~~
NAMSA biocompatibility testing for regulatory listing completed	Q210
Expanded pelvic floor study under Special Access Scheme	Q210
Ventral hernia study ethics approval	Q210
Regulatory conformity assessment application completed	Q310

==> picture [720 x 78] intentionally omitted <==

At a glance…

==> picture [682 x 183] intentionally omitted <==

----- Start of picture text -----

Group Cash
position
Fully Paid
@ 31/10/09
Ordinary 24 March
Shares 2004
$0.8 million
128.8 million
----- End of picture text -----

==> picture [682 x 124] intentionally omitted <==

----- Start of picture text -----

Group Average
Top 50
Cash Burn
Shareholders Market
(Sep QTR)
Capitalisation
76.4%
----- End of picture text -----

==> picture [720 x 78] intentionally omitted <==

For all the latest news and updates visit: www.biomd.com.au